The effects upon islet hormone secretion of highly purified preparations of secretin and of pancreozymin-cholecystokinin and of a crude gastrin-containing extract of hog antrum have been studied in acutely operated dogs. All three preparations were shown to cause a striking increase in insulin concentration in the pancreaticoduodenal venous plasma after their rapid endoportal injection in anesthetized dogs. With each hormone preparation, the peak in insulin secretion occurred 1 minute after injection, and a rapid decline was observed immediately thereafter. Whereas secretin and gastrin failed to alter significantly the pancreaticoduodenal venous glucagon or arterial glucose concentration, pancreozymin caused a dramatic rise in pancreaticoduodenal venous glucagon concentration, which reached a peak 3 minutes after injection, and hyperglycemia was noted to occur soon thereafter. Endoportal infusion of secretin and pancreozymin for 20 minutes caused responses that were sustained but qualitatively identical to the responses noted after rapid injection of the hormones. The beta-cytotropic effect of secretin was abolished by the infusion of epinephrine.
Introduction
be influenced by humoral factors of the gastro-of investigators (2-7) until 1940, when a negative report by Loew, Gray, and Ivy (8) discredited the idea. In 1964 Dupre (9) revived interest in this question with a report that a crude secretincontaining extract of hog duodenal mucosa, prepared by the method of Crick, Harper, and Raper (10) , accelerated the disappearance rate of intravenously administered glucose and increased insulin-like activity in man (11) . Pfeiffer and associates (12) and McIntyre, Turner, and Holdsworth (13) noted in 1965 that the incubation of secretin with pieces of dog and rabbit pancreas enhanced the release of insulin. More recently, preliminary in vivo evidence of an insulinreleasing effect of secretin has been reported in dogs (14) and in humans (15) . The present study was designed to explore in dogs the effects of the enteric hormones secretin and pancreozymin-cholecystokinin and the antral hormone gastrin on insulin and glucagon secretion.
Methods
Mongrel dogs were anesthetized with Nembutal after an overnight fast, and a laparotomy was performed. An indwelling needle was placed in the pancreaticoduodenal vein in the direction of venous blood flow and its position stabilized. Obstruction to venous drainage was carefully avoided. A catheter was connected to the pancreaticoduodenal needle; catheters were also inserted in a femoral vein and a femoral artery. The patency of these vascular connections was maintained by local instillation of heparin. In addition a fourth catheter was inserted into a mesenteric vein, and normal saline was infused endoportally at a constant rate of 2 ml per minute throughout each experiment.
Simultaneous samples of blood were obtained from the pancreaticoduodenal and femoral veins and from the femoral artery at frequent intervals before and after the rapid injection of the enteric hormone and before, during, and after its infusion. Mean arterial blood pressure was monitored continuously, and the hematocrit was determined at frequent intervals. All dogs included in the study were considered to have tolerated well both the surgery and the removal of blood. Plasma glucose concentration was determined by the Hoffman ferricyanide method (16) with the Technicon Autoanalyzer. Insulin was measured by the method of Yalow and Berson (17) . Plasma glucagon concentration was measured by the following modification of the previously described radioimmunoassay (18) : Rabbit antiglucagon serum [diluted to 1: 321 with 0.2 M glycine buffer (pH 8.9) containing 0.25% human albumin and 1: 100 nonimmune rabbit serum] and 0.05 ml of either unknown undiluted plasma sample or a known crystal-line beef-pork glucagon standard 1 were incubated at 40 C with 500 U of Trasylol 2 in 0.025 ml of normal saline for 2 days. After 48 hours, 30 ,uug of glucagon-mI in 0.05 ml glycine albumin buffer was added and the incubation continued for an additional 20 hours at 40 C. At the end of this time, 0.50 ml of either 0.25% human albumin or undiluted nonimmune rabbit plasma containing bromophenol blue was added, and 0.2 ml of this mixture was applied to the origin of a Whatman 3 MC paper strip. After 2 hours of chromatography in a barbital buffer, the plasma proteins migrated 18 cm from the origin, and the strips were heat-dried, bisected, and counted in a well-type gamma scintillation counter. Results were corrected for nonspecific migration by the method of Yalow and Berson (17) .
This assay has a high degree of precision; a recent analysis of replicate determinations of both known and unknown samples at all concentrations of glucagon revealed a standard error of + 1.2%. Recovery of crystalline glucagon is virtually quantitative. Although canine pancreatic glucagon appears to be immunologically similar to beef-pork glucagon (19) , until canine standards are available the quantitative accuracy of assay results in absolute terms is uncertain. It seems probable, however, on physiologic grounds that the 0.4 to 2.0 mug per ml range of normal fasting dogs is close to the true glucagon level in the fasting state (20) . Although it may still be necessary to regard the glu-agon assay as semiquantitative rather than quantitative, its precision and sensitivity make it possible to distinguish with 95% confidence differences in glucagon concentration 0.3 mjug per ml or more. It may, therefore, be regarded as fully capable of measuring small changes in plasma glucagon levels in the relative sense of immunologic equivalence to beef-pork glucagon.
The use of the proteinase inhibitor Trasylol has been shown to eliminate almost completely the problem of incubation damage by human plasma to glucagon-1"I (21) . Although incubation damage poses more of a problem in the assay of human than canine plasma (21) , Trasylol was added to the assay in this study because of the possibility that variation in release of pancreatic proteolytic enzymes into the pancreatic vein might result from manipulation of the pancreas before the experiment. It has been found that it is not necessary to collect blood specimens in Trasylol-containing tubes, however (21 ) .
Highly purified secretin, estimated to contain from 4,330 to 17,500 U per mg, and pancreozymin-cholecystokinin, said to contain 6,000 U per mg (22) , were pro-vided3 in vials containing 75 clinical U of secretin and 300 Crick U of pancreozymin. The contents of each vial were dissolved in 10 ml normal saline, giving a con- centration of 7.5 U per ml of secretin and 30 U per ml of pancreozymin. Secretin was administered through the mesenteric venous catheter by rapid injection of a dose of 1.5 U per kg or by constant infusion at a rate of 10 U per minute for 20 minutes; pancreozymin was administered by rapid injection in a dose of 100 U or by constant infusion at a rate of 30 U per minute for 20 minutes. Gastrin in the form of crude acetone powder, starting material for the purification of gastrin by the method of Tauber and Madison (23), was administered by rapid injection in a dose of 135 to 203 mU; gastrin 11, 5 prepared by the method of Gregory and Tracy (24) , was administered in the same manner in a dose of 0.06 mg.
Every lot of each hormone was assayed for insulin and glucagon. All lots employed were free of insulin. Glucagon or glucagon-like immunoreactivity was from 0 to 3.7 mug per U in secretin, from 0.02 to 0.06 mtg per U in pancreozymin, and 0.62 miug per mU in gastrin.
Results
Secretin injection. Immediately after the rapid endoportal injection of 1.5 U per kg of secretin, 4 Kindly donated by Dr. Stuart Tauber, Dallas, Texas. 5 Kindly donated by Dr. Morton Grossman, Los Angeles, Calif. a striking rise in pancreaticoduodenal venous insulin concentration was observed in each of 10 dogs ( Figure 1 ). The mean insulin level for the group rose 294% from a preinjection value of 248 IAU per ml (SD 270) to 1,175 /U per ml (SD 830) 1 minute after injection. The response was very brief, with a sharp decline occurring between 3 and 6 minutes after injection. Arterial insulin was measured in only one dog, 104, and reflected the changes in pancreatic venous insulin. There was no significant change in mean arterial glucose concentration for the group as a whole, although in some dogs a small rise was noted. However, such rises in plasma glucose were very small and followed the rise in insulin.
Pancreatic venous glucagon concentration did not change significantly. The complete findings are recorded in Table I. Pancreozymin injection. The rapid injection of 100 U of pancreozymin was also followed immediately by a sharp 484%o rise in mean pancreaticoduodenal insulin concentration in each of 1AU per ml (SD + 734) 1 minute after injection ( Figure 2 ). As with secretin, this rise was shortlived and declined rapidly between 1 and 10 minutes after injection. In contrast to the lack of a clear-cut effect of secretin upon glucagon concentration, however, the administration of pancreozymin was followed in 8 of the 10 dogs by a rapid rise in the pancreaticoduodenal venous glucagon concentration. The mean level rose from 1 mnAg per ml (SD + 0.25) before the injection to a 3-minute level of 1.78 mug per ml (SD 0.91), after which it gradually declined; the mean of all 10 peak values, irrespective of time, was 2.15 mug per ml (SD + 0.73), a rise of 1.15 mtug per ml.
Plasma glucose concentration rose slowly from 120 mg per 100 ml (SD 10.3) to a peak of 155 mg per 100 ml (SD + 25.8) at 10 minutes. The time of the rise in glucose concentration was far too late to be causally related to the rise in insulin.
The individual results of these experiments are recorded in Table II. Gastrin injection. Rapid endoportal injection of a gastrin-containing extract of hog antrum in three dogs was followed by a rapid 385% rise in the mean pancreaticoduodenal venous insulin concentration from a preinjection value of 193 MuU per ml (SD 123.3) to a peak of 937 uU per ml (SD + 661.4) 1 minute after injection ( Figure  3 ). Again a rapid decline occurred, with a return to the base-line value within 6 minutes. A 0.19 mug per ml rise in mean pancreaticoduodenal venous glucagon concentration was noted at 1 min-ute after injection in parallel with a 4 mg per 100 ml rise in glucose concentration. The administration of 0.06 mg of pure porcine gastrin II elicited the same type of insulin response; the pancreaticoduodenal insulin level rose more than tenfold, from 169 to 1,835 MAU per ml 3 minutes after the injection. Glucagon content of injected hormone solutions and its effect on the results. Glucagon has been concentration measured. Secretin solutions conshown to have potent insulin-releasing activity in tained from 0 to 3.7 m/g per U, pancreozymin man (25) (26) (27) and in dogs (20) , even in small from 0.02 to 0.06 mug per U, and gastrin 0.62 doses of less than 100 mpg; since glucagon-like mug per U. These quantities are known to be immunoreactivity is present in the gut (28, 19 , insufficient to cause a rise in insulin of the magni-29), its presence as a contaminant in preparation tude observed (20) , although potentiation by gluof gut hormones would not be unexpected and cagon of the effect of another hormone is a possimight play a role in the rise in insulin excretion bility. The large rise in glucagon concentration observed. For this reason, in each experiment a observed after the injection of pancreozymin cansample of the hormone solution was removed from not be explained by its glucagon content; however, the syringe before its injection and its glucagon the small rise in pancreatic venous glucagon ob- served after gastrin injection may well be the consequence of its glucagon contaminant. It seemed barely possible that the rise in pancreaticoduodenal venous glucagon concentration observed after pancreozymin administration was a consequence of reflux of the glucagon contaminant from the portal vein into the indwelling pancreatic venous needle. For this reason, six pancreozymin experiments were performed with a catheter inserted into the pancreatic vein in a retrograde direction and tied in place; thus, the entire pancreaticoduodenal vein effluent was collected, making reflux from the portal vein impossible. In these experiments, the rise in mean glucagon concentration after the injection of pancreozymin was substantially greater than in the other experiments, with a peak at 3 minutes of 3.19 mjug per ml as compared with 1.78 mug per ml (Table IV) .
These results not only exclude reflux of glucagon from the portal vein as a cause of the rise in glucagon concentration, but they point to the pancreas rather than to the gut as the principal source of the pancreozymin-induced rise in glucagon concentration.
Effects of inactive secretin and other polypeptide hormones. Inasmuch as each of the four hor-mones examined thus far, secretin, pancreozymin, gastrin, and glucagon, have been shown to elicit a very prompt and short-lived rise in pancreaticoduodenal venous insulin concentration when injected endoportally in anesthetized dogs, it seemed possible that this might be a nonspecific response to the rapid injection of a polypeptide. For this reason, the effects on insulin secretion of several other polypeptide hormones not of gastrointestinal origin and of a preparation of secretin that had been shown to have lost its secretagogue activity (22) were studied.
The administration via a peripheral vein of large doses of three other polypeptide hormones, ovine growth hormone, vasopressin, and ACTH, failed to elicit the same pattern of insulin response as observed after injection of the gastrointestinal hormones. After 20 U of vasopressin, insulin secretion seemed to decline at first and then rise in parallel with the blood glucose level (Figure 4) . One mg ACTH seemed to induce a small early rise in insulin concentration lasting 3 minutes and an apparent decline in glucagon concentration (Figure 4) . In a 2-mg dose, ovine growth hormone had no immediate effect on insulin concentration, but a late rise in plasma glucose and insulin concentration was noted (Figure 4 ). Al- though only one experiment with each of these hormones was performed, it would appear that they do not resemble the gastrointestinal hormones with respect to their effect upon insulin release. The endoportal injection of 1.7 ,tg of the inactive secretin preparation failed to elicit the customary response in insulin secretion (Table V) to be 20 ml per minute, the total increment in insulin output resulting from the endoportal injection of these three hormones in these experiments is not more than a few milliunits. Its physiologic importance can, therefore, be questioned.
To determine if sustained endoportal infusion of secretin would elicit a sustained increase in insulin secretion, we infused secretin at a rate of 10 U per minute in a group of five dogs. The mean insulin level ( Figure 6 ) rose initially from 173 uU per ml (SD + 91.7) to a peak at 2.5 minutes of 604 MuU per ml (SD 406.8), an increase of 249%, and declined to 435 uU per ml (SD + 417.3) 5 minutes after the start of the infusion. There appeared to be a slight downward trend in the mean pancreaticoduodenal insulin concentration throughout the remainder of the infusion, and its rate of decline accelerated only slightly when the infusion ended. The mean level of pancreaticoduodenal venous glucagon did not change significantly during the infusion, nor did the small rise in mean arterial glucose concentration appear to be significant. The individual results are recorded in Table VII. If we assume the same overestimated value of 20 ml per minute for pancreatic blood flow, it can be calculated that insulin secretion was augmented by approximately 105 mU during the 20-minute infusion of secretin, i.e., by 5.24 mU per minute. Effects of endoportal infusion of pancreozymin.
The effects upon insulin and glucagon secretion of pancreozymin infused endoportally at a rate of 30 U per minute for 20 minutes were examined in a group of four dogs. The mean pancreaticoduodenal concentration of insulin rose rapidly from a preinjection level of 127 ptU per ml (SD 17.4) to a peak of 1,191 MU per ml (SD 319.3) at 10 minutes, a rise of more than 600% (Figure 7) ; during the last 10 minutes of the infusion, there was a decline to a mean level of 968 uU per ml, which was still more than six times the preinjection level. When the infusion was terminated, the insulin level fell to 372 ,LU per ml (SD + 164.8) within the first 10 minutes and reached the base-line value within 25 minutes after the end of the infusion. If we estimate a pancreatic blood flow of 20 ml per minute, it can be calculated that a total of 346 mU of insulin was added during the 20-minute infusion of pancreozymin, or about 17.3 mU per minute. The changes in pancreatic venous insulin were reflected by appropriate, though smaller, alterations in arterial insulin concentration. venous plasma also rose promptly after the start of the infusion from a preinjection level of 1.11 m/ug per ml (SD 0.64) to 2.16 mnug per ml (SD + 1.05) at 5 minutes and remained at or above this level until the termination of the infusion, at which point it declined rapidly to a level of 1.46 m/g per ml 10 minutes after termination. If we assume a pancreatic blood flow of 20 ml per minute, glucagon secretion was augmented by approximately 408 ming or 20.4 mi/g per minute during the infusion. The changes in pancreatic venous glucagon were reflected by small changes in arterial glucagon levels.
The mean arterial plasma glucose level rose from a preinjection level of 123 mg per 100 ml (SD + 11.1) to 140 mg per 100 ml (SD + 14.2) during the first 5 minutes of the infusion. During the second 10 minutes, however, it ascended more rapidly to a level of 182 mg per 100 ml (SD + 35.5) at 10 minutes and reached a peak level of 208 mg per 100 ml (SD + 49.3) at the end of the infusion. Upon termination of the infusion, the mean plasma glucose concentration declined at a gradual rate of 2.2 mg per minute and required more than 30 minutes to reach the preinjection level. The individual results of all experiments are recorded in Table VIII .
Discussion
These results provide evidence of a relationship between the hormones of the gastrointestinal tract and those of the islets of Langerhans. They thus support the 60-year-old concept that secretin is biologically capable of augmenting insulin secretion. These studies also reveal, however, that (20) in dogs. In the latter study, the pattern of the response of pancreaticoduodenal insulin concentration and of arterial plasma glucose concentration to the rapid endoportal injection of 1 pg of glucagon was distinctly different from the response to the three hormones studied here; after glucagon injection, the mean insulin and glucose levels rose concomitantly to a plateau peak at 3 to 6 minutes after injection and remained above the preinjection level for almost 20 minutes. The patterns of response for each of the four beta-cytotropic hormones are compared in Table IX . The ubiquity of "glucagon-like" biologic activity (31, 32) and immunoreactivity (19, 28, 29) raises the possibility of its presence as a contaminant in other hormone preparations of the gut.
Furthermore, there appears to be a structural similarity between glucagon, composed of 29 amino acids (33) , and secretin, composed of 27 (34) , that has led to the suggestion of an overlap in their biologic properties (35) . The crude gastrin preparation employed here contained from 17 to 38 mpAg of glucagon-like immunoreactivity per milligram, but since glucagon-free gastrin II caused a similar response, it seems unlikely that glucagon was an important factor in the observed response. Pancreozymin contained only 0.02 to 0.06 mpg per U of glucagon-like immunoreactivity, not enough to have played a significant role in the genesis of the insulin response. Finally, glucagon-like immunoreactivity of the secretin preparation ranged from 0 to 3.9 m/ug, not nearly enough to stimulate insulin secretion to the degree observed. (Despite a possible structural similarity of the glucagon and secretin molecules, the absence of hyperglycemia after the endoportal injection of large doses of secretin and the immunologic displacement by 20 pug of secretin of the equivalent of only 0.0009 pug of glucagon reveal major biologic and immunologic differences.)
It would appear that the pattern of insulin release induced by gastrin, secretin, and pancreozymin is a characteristic of these gastrointestinal hormones and is not shared by any of the nongastrointestinal polypeptides studied. The insulinogenic effect of ACTH, previously reported in vitro by Sussman, Vaughn, and Timmer i(36), differed both in timing and magnitude.)
In these experiments, pancreozymin had a direct glucagon-releasing effect and is consequently the first hormone thus far shown to have this property. Although the pancreozymin prepara-tion did contain traces of glucagon, the quantities were far too low to account for a rise in pancreatic venous glucagon of the magnitude and duration observed. The relative timing of the arterial hyperglycemia and the hyperglucagonemia suggests that the former could be a consequence of the release of endogenous glucagon rather than of a glycogenolytic effect of the pancreozymin itself. The occurrence of hyperglycemia in the retrograde catheterization experiments does not weigh against this possibility, since venous channels other than the pancreaticoduodenal vein drain the endocrine pancreas and arterial glucagon levels rose in those experiments.
The metabolic importance of the quantities of insulin released in response to the enteric hormones is not apparent from these data, since, surprisingly, glucose did not decline significantly and free fatty acid levels were not measured. However, Meade has observed a fall in FFA concentration after the administration by peripheral vein of much smaller doses of pancreozymin to dogs (30) .
Proof of the physiologic significance of the enteric hormones in the control of islet hormone secretion will require demonstration that similar responses in islet hormone secretion are provoked by maneuvers that cause the secretion of endogenous enteric hormones. Thus far, reported attempts to enhance insulin secretion by intraduodenal instillation of acid, a stimulus for secretin secretion have been unsuccessful (37) . On the other hand, the intraduodenal instillation of protein hydrolyzates has been shown to cause a striking rise in both insulin and glucagon secretion (38) . Pancreozymin, which is secreted in response to amino acid ingestion (39) and which duplicates qualitatively the effects of amino acids upon islet hormone secretion, could be that hormone.
The fact that four hormones of the gastrointestinal tract, gastrin, secretin, pancreozymin-cholecystokinin, and "glucagon" of intestinal origin (40) , all have insulin-releasing activity suggests a chain of beta-cytotropic hormones extending from the antrum to the ileum. Early augmentation of insulin secretion by these hormones to a degree appropriate to the quantity and type of nutrients ingested before the attainment of peak blood levels of substrates would permit prompt substrate disposal without excessive hypergly-cemia or hyperaminoacidemia, which would occur after large meals if insulin release were entirely dependent upon arterial substrate concentration.
